BioVaxys Technology Corp. is developing its patented DPX™ platform to address the challenges of lipid nanoparticles (LNPs) in mRNA vaccine delivery. Learn how DPX improves stability, immune responses, and manufacturing economics as the mRNA vaccine market projects $48 billion growth by 2030.
Browsing: News
[ad_1] By Daphne Psaledakis and David Brunnstrom WASHINGTON (Reuters) -The United States on Wednesday imposed hundreds of sanctions targeting Russia,…
[ad_1] Chaya Eri, President and Chief Creative and Merchandising Officer of RH (NYSE:), recently sold a significant portion of the…
[ad_1] New York, New York–(Newsfile Corp. – January 15, 2025) – WHY: Rosen Law Firm, a global investor rights law…
[ad_1] By Jasper Ward WASHINGTON (Reuters) -U.S. Representative Mike Turner said on Wednesday he will no longer serve as chairman…
[ad_1] SAN MATEO, CA—King James Winston, the Chief Administrative Officer and General Counsel of Guidewire (NYSE:) Software (ETR:), Inc. (NYSE:GWRE),…
[ad_1] By Jonathan Stempel NEW YORK (Reuters) -A judge has dismissed New York City’s lawsuit seeking to hold Exxon Mobil…
[ad_1] New York, New York–(Newsfile Corp. – January 15, 2025) – WHY: Rosen Law Firm, a global investor rights law…
[ad_1] Demetrios Vaiopoulos, a director at Gryphon Digital , Inc. (NASDAQ:GRYP), recently acquired shares of the company, according to a…
[ad_1] These transactions reflect Olivan’s ongoing management of his equity stake in Meta Platforms, a company renowned for its social…